Financial Lp Hrt Purchases 2,159,052 Shares of Clearmind Medicine (NASDAQ:CMND) Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt bought 2,159,052 shares of the business’s stock in a transaction on Wednesday, June 10th. The shares were purchased at an average cost of $0.15 per share, with a total value of $323,857.80. Following the transaction, the insider owned 2,063,266 shares in the company, valued at approximately $309,489.90. The trade was a -2,254.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The stock was sold at an average price of $0.12, for a total transaction of $27,022.92.

Clearmind Medicine Stock Performance

Shares of CMND stock remained flat at $3.34 during trading hours on Friday. 160,481 shares of the stock were exchanged, compared to its average volume of 1,154,156. Clearmind Medicine Inc. has a 12 month low of $2.10 and a 12 month high of $524.00. The business has a fifty day moving average price of $6.37 and a two-hundred day moving average price of $17.01. The firm has a market cap of $3.40 million, a P/E ratio of -0.02 and a beta of 0.64.

Clearmind Medicine (NASDAQ:CMND) last announced its earnings results on Thursday, March 12th. The company reported ($33.20) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.